Transthyretin is an amyloidogenic protein associated with several amyloidosis, namely familial amyloidotic polyneuropathy, familial amyloidotic cardiomyopathy, and central nervous system selective amyloidosis, familial rare diseases caused by single point mutants, and senile systemic amyloidosis associated with wild-type TTR. The current model for amyloid fibril formation involves initial dissociation of the native TTR tetramer into non-native monomers which associate into soluble oligomers and protofibrils that evolve to mature amyloid deposits. A number of efforts are addressed to identify small molecules targeting the formation, clearance, or assembly of toxic aggregates as a promising therapeutic strategy to treat amyloidosis. This review classifies and summarizes the different strategies and assays that have been developed in vitro, ex vivo, and in vivo as tools to screen libraries of compounds or to test compounds from rational design in the search of drug candidates for the treatment of TTR-associated amyloidosis. Depending on the property they measure, the assays are classified as: a) in vitro assays that monitor protein aggregation and/or fibril formation, b) in vitro assays that monitor binding to native protein, c) ex vivo TTR plasma selectivity assays, d) in vitro assays for tetrameric TTR stabilization, e) cellular assays, and f) animal models to evaluate amyloidosis inhibitors.
INTRODUCTION
Amyloid diseases are caused by the deposition of any of the 27 currently identified non-homologous human proteins [1] , characterized by the formation of highly-ordered fibrils that are present in amyloid deposits along with many accessory proteins [2] [3] [4] [5] [6] [7] [8] [9] . Human transthyretin (hTTR) is an amyloidogenic protein associated with senile systemic amyloidosis (SSA), caused by wildtype (wt) TTR and affecting up to 25 % of the senile population, familial amyloidotic polyneuropathy (FAP), produced by singlepoint mutants, like V30M or L55P, where the pathology can develop at an early age, familial amyloidotic cardiomyopathy (FAC), mainly associated with V122I, and T60A variants, and central nervous system selective amyloidosis (CNSA), the main representative being the A25T and D18G TTR variants [10] [11] [12] ( Table 1) . Transthyretin is a 55 kDa homotetrameric protein (127 aa/subunit) that, together with thyroxine binding protein and albumin, is a thyroid hormone (T4) carrier in plasma and the major T4 transporter in the cerebrospinal fluid. In complex with the retinol binding protein it acts as a retinol transporter [13] . The 3D structure reveals the assembly of two dimers that form a central hydrophobic channel containing two symmetrical T4 binding sites ( Fig. 1) with different dissociation constants, reflecting negative cooperativity [14] . The distribution of FAP and FAC mutations within the three-dimensional structure of TTR (Fig. 2) shows that mutations are not restricted to structurally rigid parts of the molecule, nor are they concentrated at the monomer interaction sites [15] [16] [17] .
Amyloid fibril formation (Fig. 3) is initiated by TTR tetramer dissociation into dimers and monomers that evolve to a misfolded or non-native monomer intermediate. Depending on its thermodynamic stability, the native monomer produces partially unfolded amyloidogenic monomeric species that start an intermolecular aggregation process involving a number of states through soluble oligomers and leading to mature fibrils [18] [19] [20] [21] [22] . Several studies have shown that TTR intermediates (protofibrils and soluble oligomers) rather than mature fibrils are the toxic species in cell cultures and may play a role in pathogenesis [23, 24] . Therefore, therapeutic strategies are nowadays mainly focusing on either tetramer stabilization or preventing the formation of fibrils and prefibrillar toxic intermediates [4] .
*Address correspondence to this author at the Department of Bioengineering, Institut Químic de Sarrià, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain; Tel: +34-932672000; Fax: +34-932056266; E-mail: antoni.planas@iqs.es Although point mutations of TTR are a factor in FAP and FAC, the mechanisms by which TTR amyloidosis are triggered in vivo remains unclear. Failure in the protein degradation pathway in lysosomes (where acidic physiological conditions accelerate fibril formation) due to protease resistance of soluble amyloid-like oligomers has been proposed [25] , but this model does not explain why deposits are extracellular. Post-translational modifications like glycation, oxidation, and sulfonation, also affect TTR fibrillogenesis [26] . In vitro, TTR amyloidosis can be induced under acidic conditions. As shown in Fig. (3) , the general model for fibril formation starts with native tetramer dissociation into monomers. These monomers can suffer conformational changes which allow them to associate forming soluble oligomers that selfassemble leading to the final amyloid fibril. The amyloidogenic potential of TTR variants correlates with their tendency to aggregate in solution [27] .
Liver transplantation is currently the only therapy for FAP and FAC, with limited clinical success [28] , and not applicable to mutants that develop amyloidosis in the central nervous system where TTR is also synthesized. Stabilization of the tetramer in the asymptomatic phase seems a promising option for a therapeutic intervention. Currently a number of efforts are addressed to the screening of small molecules targeting the formation, clearance, or assembly of toxic aggregates as a promising strategy to treat amyloidosis [8, [29] [30] [31] . Other potential therapeutic strategies are also being explored but less developed such as immune therapy [32] , and gene therapy with small interfering RNAs, antisense oligonucleotides, and single-stranded oligonucleotides [33] [34] [35] [36] .
Binding of small molecule ligands to the thyroxine (T4) binding sites of TTR stabilizes the TTR tetramer and slows tetramer dissociation and amyloidogenesis in vitro [8, [29] [30] [31] 37] . Also compounds binding to secondary sites or even to initial non-native and non-cytotoxic species may slow down the amyloidogenic pathway. Compounds with a variety of core structures, including NSAIDs, natural products, and other compounds have been tested as amyloidosis inhibitors which can be delivered in a useful therapeutic concentration. Competitive ligand binding to native TTR will not impair hormone transport as TTR only transports 10 % of thyroid hormones in plasma, and most of the plasma TTR remains unbound. Two compounds have been tested in clinical trials for TTR amyloidoses: a NSAID diflunisal [38] and Tafamidis (a benzoxazole derivative) [39] , where the latter has been recently approved in Europe for FAP. Other clinical trials have also been initiated for doxycycline plus tauroursodeoxycholic acid in TTR amyloidosis [40] . To evaluate TTR amyloidosis inhibitors, different assays have been developed in vitro, ex vivo, and in vivo as tools to screen libraries of compounds or to test compounds from rational design in the search of drug candidates for the treatment of TTR-associated diseases. In this minireview we classify and summarize the different strategies and assays that have been recently proposed, detailing what they measure and their applicability for inhibitor screening and evaluation.
ASSAYS FOR THE SCREENING AND EVALUATION OF INHIBITORS
A number of biophysical methods to monitor fibrillogenesis and to analyse protein-ligand interactions [41, 42] have been implemented for the screening and characterization of TTR fibrillogenesis inhibitors. Based on the general scheme depicted in Fig. (3) that describes the proposed model of TTR fibrillogenesis, small molecule ligands addressed to inhibit the overall process can act on any step along the pathway: ligands to the native protein, which may stabilize the tetrameric form preventing or reducing dissociation, molecules interacting with monomeric species or initial soluble aggregates that may block progression into protofibrils and amyloid, or molecules acting as disrupters of fibrils to revert mature fibrils formation. The last strategy, small molecule disruption of TTR aggregates, may result in toxic conformers that may also seed other TTR molecules to adopt the toxic conformation. Care should be taken to ensure that strategies aimed at inhibiting fibril formation do not cause a corresponding increase in the concentration of toxic oligomeric species [43] . Fig. (4) summarizes a selection of core structures representing the different families of small molecules tested as potential TTR amyloidosis inhibitors, most being halogenated biaryl analogs of T4 and NSAID-related compounds. The main focus of current screening programs is to find hits as inhibitors acting as ligands of native TTR which will stabilize the tetramer and inhibit dissociation into monomers, the initial step required for fibril formation (stabilization hypothesis [8] ). Nevertheless, other steps in the amyloidogenesis pathway are also targets for inhibition, although fewer compounds have been reported acting by these alternative mechanisms (i.e. fibril disrupters such as the anthracycline 4'-iodo-4'-deoxydoxorubicin (IDOX) [44] and tetracyclines as doxycycline, Fig. 5b) .
From an overview of the different methods reported in the literature, assays can be grouped in those that monitor the end products (formation of protein aggregates or fibrils), and assays that measure binding to and stabilization of the native tetramer. On the other hand they can also be classified as in vitro assays, using isolated (recombinant) TTR protein, or cellular assays, monitoring in vivo either fibril formation or cytotoxicity. In all cases, small molecules are added to the system (in vitro, ex vivo, or cellular) to evaluate the effect on a property related to a given step in the pathway depicted in Fig. (3) . Besides fibrillogenesis inhibition, selectivity for TTR over other plasma proteins and performance on animal models of amyloidosis are further assays to assess possible therapeutic effects.
A. In Vitro Assays that Monitor Protein Aggregation and/or Fibril Formation
Based on the property of amyloidogenic proteins to form aggregates or fibrillar deposits, these methods monitor the formation of fibrils or insoluble aggregates and its inhibition by added small molecules (protein fibrillogenesis inhibitors). They can be either end-point methods, measuring the final amount of aggregates or fibrils after a given incubation time in the presence of different inhibitor concentrations, or kinetic methods, monitoring the time course and the rate at which they are produced.
In vitro assays use purified recombinant protein (wt TTR or clinically relevant TTR single-point mutants) where amyloidosis or aggregation is induced by lowering the pH of the protein solution (acid-induced amyloidosis [45, 46] , commonly to pH 4.2-4.4 for wt TTR and some low amyloidogenic mutants, or higher pH (6-7) for highly amyloidogenic variants). These are the most common assays in general screenings for potential amyloid inhibitors since they are easily implemented in medium or high throughput screening (HTS) formats in tubes or microwell plates. Depending on whether total insoluble protein or specific amyloid formation is monitored, these in vitro assays are further classified in:
a.1. Turbidimetric Assays
They monitor turbidity (absorbance at 330 or 400 nm) or light scattering due to protein precipitation under acidic conditions [45] [46] [47] . Fibrils and/or amorphous aggregates are formed depending on the pH and temperature, but these methods quantify total insoluble protein since turbidity does not give information on the nature of the aggregate species. Most commonly they are implemented as an "end point assay" where the total insoluble protein in the absence and presence of potential inhibitors is quantified after long incubation periods (typically 72 h). The turbidimetric end-point assay has been extensively used for the screening of small molecules such as NDAIDs, natural products, and many other compound families including biphenyls, salicylics, anthranilics, etc. (i.e. [48] [49] [50] [51] [52] [53] [54] ).
Also a kinetic turbidity assay has been developed, using a highly amyloidogenic TTR variant (such as Y78F), which quantifies the initial rate of aggregate formation in the absence and presence of different concentrations of potential inhibitors [55] . Initial rates of protein aggregation at different inhibitor concentrations follow a monoexponential dose-response curve from which inhibition parameters are calculated (IC 50 , inhibitor concentration at which the initial rate of protein aggregation is onehalf than without inhibitor, and RA%, percentage of reduction of fibril formation at high inhibitor concentration). The method was optimized for short analysis time (less than 1.5 h) with high sensitivity to discriminate between inhibitors, and implemented in high throughput format in microtiter plates. With this assay, a large number of compounds have been tested. In particular it has been used for the screening of series of iodinated and non-iodinated diflunisal and salicylic derivatives, showing that iodination notably increases the inhibition potency (iodination hypothesis) [56] [57] [58] [59] [60] .
a.2. Thioflavin T and Other Dye Binding Assays
Congo Red has been the classical dye for staining amyloids in tissues ex vivo, where it shows birefringence under cross-polarized light. [61] [62] [63] . CR binds to fibrils and measurement of the absorbance of bound CR is a qualitative evidence of the fibrilar nature of the deposits. But CR has also shown to be able to bind to non-amyloid structures [64] . Therefore, CR is not used for in vitro screening of potential TTR amyloidogenesis inhibitors. The amyloid specific dye thioflavin T (ThT, excitation at 442 nm and emission between 450 and 550 nm with a maximum at 482), which results in a large fluorescence enhancement upon binding to fibrils (but not to amorphous aggregates) [65] [66] [67] [68] is commonly used in inhibitor screening programs. It complements measurements of total protein aggregation estimated by turbidity or light-scattering of the samples, where ThT is added at the end of the incubation to quantify fibrils in the precipitated protein, but also can be used for continuous monitoring of fibril formation when added to the protein solution at the beginning of the acid-induced fibrillogenesis [69] . ThT also binds to soluble protofibrils before they become insoluble by assembly to higher order aggregates, therefore being able to monitor the effect of inhibitors on the early stages of fibrillogenesis where no turbidity is yet observed. When used for inhibitor screening caution has to be taken due to the possible fluorescence quenching by the tested compounds [70] . Besides thioflavin T, other fluorescent probes have been developed and used for amyloid fibril detection and characterization of amyloidogenic protein states: small fluorescent molecules such as 4-(dicyanovinyl)-julodine and derivatives of 1-amino-8-naphtalene sulfonate [71] , luminescent conjugated oligothiophenes for real-time imaging of protein aggregates [72] , or antibody stains to monitor oligomer size and distributions [73] .
a.3. TEM and AFM Monitoring of Fibril Formation
Transmission electron microscopy (TEM) and Atomic Force Microscopy (AFM) are common techniques to observe the morphology of protein aggregates and fibrils. As revealed by electron microscopy, amyloid deposits generally consist of straight or coiled fibrils, 7.5 to 10 nm in width and up to several µm in length [74] [75] [76] . A molecular model for in vitro assembled TTR amyloid-like fibrils has been obtained by a combination of TEM, AFM, and STEM (quantitative scanning TEM) [77] . In inhibition studies, TEM is useful to visualize the effects on morphology changes, but it is not practical for screening due to the timeconsuming sample preparation. TEM has been also used to evaluate TTR fibril disrupters such as 4'-iodo-4'-deoxydoxorubicin (IDOX) and tetracyclines ( Fig. 5b) , which render non-cytotoxic species [78] . The morphological features of wt TTR amyloid protofibrils that appear in the early stages of aggregation have been investigated by AFM [79] . Interestingly, TTR protofibrils obtained under mild acidic conditions appear as flexible filaments that bind amyloid markers (Congo Red and ThT), but they do not form mature amyloid-like fibrils. It is suggested that wt TTR can form metastable filamentous aggregates that may represent an important transient state along the pathway towards the formation of cytotoxic species.
B. In Vitro Assays that Monitor Binding to Native Protein
Since ligands that bind to native TTR stabilize the tetrameric native form preventing its dissociation into amyloidogenic monomers and hence reducing fibrillogenesis, potential amyloidosis inhibitors can be assayed by determining their binding properties using different techniques. Ligands can either bind to the T4-binding site (allowing competitive binding assays) or to secondary binding sites which can also result in tetramer stabilization. These assays use purified TTR (wt or target mutants relevant to a specific TTR-associated disease) under conditions where aggregation/ fibrillogenesis is negligible not to interfere with binding to native protein. Reported methods can be classified as non-competitive and competitive assays.
B.1. Non-Competitive Binding Assays
Different techniques have been reported to monitor ligand binding to native TTR. In non-competitive methods, direct binding is monitored without distinguishing for binding to the T4-binding site or to secondary binding sites, information that has to be obtained by other methods such as competitive binding assays or Xray crystallography of the protein-ligand complexes.
b.1.1. Isothermal Titration Calorimetry (ITC)
Calorimetric techniques provide a rapid route to a full thermodynamic characterization of a biomolecular interaction [80] . For small molecule ligands, dissociation constants (K d ), stoichiometry, ΔH and ΔS of binding are directly obtained. ITC measurements on native TTR show that for most of the good ligands, the two T4 binding sites have negative cooperativity, the dissociation constants being in the low nM range for the first K d , and high nM or µM range for the second K d [81] . Negative cooperativity is an intrinsic property of T4 (natural ligand) binding to TTR (12) , the structural bases of which [82] have been extensively analyzed by computational methods [83, 84] . But in terms of fibrillogenesis inhibition, it has been shown that occupancy of a single binding site is sufficient for stabilizing the native state [85] , which enables lower doses of inhibitors mitigating potential side effects.
b.1.2. Surface Plasmon Resonance (SPR)
As a general method to measure protein-ligand interactions [86, 87] , SPR has been used to evaluate potential TTR ligands, in either non-competitive and competitive formats (see below). In ligand binding experiments, biotinylated TTR is immobilized on a streptavidin-coated sensor SPR chip. Next, the ligand is flowed over and the sensorgram is recorded. From the kinetic data the corresponding equilibrium binding parameters are calculated. In this assay, potent kinetic stabilizers have a K d in the low nM range [88] .
These non-competitive methods (ITC, SPR) are not normally used for screening but rather for detailed biophysical characterization of selected compounds in order to assess and quantify binding [88] .
b.1.3. Affinity Capillary Electrophoresis
ACE is an analytical approach in which the migration patterns of interacting molecules in an electric field are used to identify specific binding and to estimate binding constants on the basis that the complex has different electrophoretic properties from those of the interacting species [89, 90] . It has been applied to the analysis of NSAIDs (flufenamic acid, niflumic acid, diclofenac, flurbiprofen, ketoprofen, fenoprofen, suprofen) and other compounds (such as apigenin, amlodipine, resveratrol, warfarin and thioflavin T) as TTR ligands with good results [91] . The configuration frontal-analysis-capillary electrophoresis (FA-CE) is the most preferable in terms of protein consumption, rapidity and reliability. The remarkable advantage is that a protein in different conformational states (globular or fibrillar) can be investigated without immobilizing the molecule on a stationary phase, thus excluding the possible alteration of the protein's tertiary structure. ACE is currently used in ligand screening of other amyloidosis, most notably β2-microglobulin in dialysis-associated amyloidosis [92] .
b.1.4. Ligand Complexes by Mass Spectrometry
The use of mass spectrometry (MS) to investigate proteinprotein and protein-ligand interaction has been reported extensively [93] [94] [95] [96] . It has been shown that under appropriate conditions, solutions of apo TTR and apo TTR:RBP:retinol give rise to mass spectra containing peaks assigned to tetrameric and hexameric complexes [97, 98] . A strong correlation exists between the instability of the tetramer in the gas phase and the amyloidogenicity of the protein variant. In the presence of TTR ligands conditions could be found where a strong correlation exists between the solution equilibrium and the proportion of tetramer within the mass spectrum [97] . By using reference ligands to the T4-binding site of TTR (thyroxine, flurbiprofen, flufenamic, diclofenac, diflunisal, resveratrol, etc., Fig. 5a ), MS conditions were adjusted to monitor the complexes and to evaluate the ability of the ligands to stabilize the tetrameric structure. The method has been successfully applied to the screening of TTR amyloid inhibitors [99] . It was found that T4 and the tested ligands, upon binding to TTR, do not inhibit association of transthyretin with holo retinol binding protein [99] .
B.2. Competitive Binding Assays
Competition of small molecules with the natural ligand (thyroxine) for the T4-binding sites of native TTR has been implemented in different formats for screening of libraries in either low or high throughput assays.
b.2.1. T4 Binding Competition Assay
As standard competitive assay, it is used to evaluate selected compounds for their potency in binding to TTR specifically at T4 binding sites. A solution of native TTR is incubated with trace amount of radiolabelled [ 125 I]T4 plus increasing concentrations of the compound to be assayed. Upon equilibrium (overnight incubation), bound [ 125 I]T4 is separated from unbound T4 by gel filtration chromatography. Likewise, unlabeled T4 is used as a control. Quantification of the displaced labeled T4 correlates with the relative binding affinity of the compound. From the doseresponse curve, the EC 50 value (inhibitor concentration at which half of the bound T4 is displaced) for each compound is determined. The relative potency for the inhibition of binding of T4 is defined as the ratio EC 50 (T4)/EC 50 (compound) [100] [101] [102] . A library of diflunisal analogs with different substitutions at the carboxylic acid function resulted in higher affinity to TTR upon iodination (iododiflunisal derivatives). Iodinated compounds were always more potent at displacing T4 than their non-iodinated counterparts. Affinity differences that go up to two and three orders of magnitude can be observed for some compound, which correlate with higher acid-induced fibrillogenesis inhibition as determined by the kinetic turbidity assay [56] . The lack of correlation found in other families (i.e. isatins, Fig. 4 ) in which good fibrillogenesis inhibitors do not show affinity for tetrameric TTR (as determined by T4 displacement for binding to the T4 binding site, and ITC for binding to any site on the native TTR) indicate that these compounds operate by a mechanism other than tetramer stabilization, probably by inhibiting some further step in the fibrillogenesis pathway [57] .
b.2.2. SPR Biosensor Competitive Inhibition Assay
The principle of this biosensor assay is based on a competitive binding assay where thyroxine (T4) is immobilized on the SPR sensor surface, and preincubated TTR protein with a small ligand to be tested is flowed over the sensor chip. Binding of TTR to the sensor surface will be inhibited given an interaction between the analyte and TTR in solution, resulting in a lower response dependent on analyte concentration and affinity. The assay has been implemented for the fast screening of chemicals with thyroxine transport disrupting activity, using the main thyroid hormone transport proteins, T4 binding globulin (TBG) and transthyretin (TTR) [103, 104] .
b.2.3. Fluorescence Conjugate Competition Assay
A stilbene derivative bearing a photoreactive phenyl ester group (TTR FP covalent probe, Fig. 5c ) selectively binds to the T4 binding site of native (tetrameric) TTR, and covalently reacts with Lys-15 upon irradiation creating a fluorescent TTR-stilbene conjugate [105] [106] [107] . In the presence of other TTR ligand that competes for the T4 binding sites, the emitted fluorescence is decreased, allowing to develop a competitive binding assay to screen compounds as TTR ligands (kinetic stabilizers) [108] . It is shown that the lower the TTR-stilbene conjugate fluorescence, the greater the binding selectivity and potency of the candidate.
Although not yet implemented the assay could be adapted for high throughput screening applications [108] . Importantly, this assay can be used directly on human blood serum as source of TTR to discover potent TTR kinetic stabilizers that also bind selectively to TTR over the other plasma proteins, since the photoreactive ligand is highly selective for TTR in preference to many other proteins that make up human plasma [105] . Thus, it replaces two assays previously required, an assay for ligand binding to TTR and another for TTR plasma selectivity (see below) [108] .
b.2.4. Fluorescence Polarization Displacement Binding Assay
Fluorescence polarization (FP) is used to study molecular interactions by monitoring changes in the apparent size of a fluorescently labeled molecule. Binding is reflected by an increase in the FP signal, which is proportional to the decrease in the rate of tumbling of a fluorescent ligand upon association with macromolecules such as proteins [109, 110] . It has been recently reported the use of a fluorescent probe for high throughput screening of a large library of compounds as ligands of TTR based on a competitive binding assay [88] . A fluorescent ligand consisting of a diclofenac analog derivatized with fluorescein isothiocyanate through a triethylene glycol linker (FP probe, Fig. 5c ) binds to native TTR with a K d of 13 nM. In a displacement assay, ligands to be tested are added to preincubated TTR with the fluorescent probe, monitoring the decrease in fluorescence polarization. The assay has been applied for the largest high throughput screening (HTS) of TTR ligand reported so far. Screening of a 130000 small-molecule library from the Stanford HTBC library for compounds that displace the probe from the T4 binding sites of TTR identified new hits that were potent kinetic stabilizers of TTR and prevented tetramer dissociation, partial unfolding, and aggregation of wt and the most common cardiomyopathy-related TTR variant, V122I [88] .
C. Ex Vivo TTR Plasma Selectivity Assays
In vitro fibril formation assays are performed with recombinant TTR in buffer and do not account for the possibility that a putative TTR amyloidogenesis inhibitor could bind with high affinity to another protein in a complex biological fluid like human blood, reducing its effectiveness against TTR amyloidogenesis. Therefore, plasma selectivity assays have been employed to further assess whether putative inhibitors (positives from other assays) bind to TTR over other plasma proteins. Historically two binding selectivity assays have been extensively used.
c.1. Plasma Binding Selectivity by T4 Displacement
There are three main proteins in plasma that bind T4: thyroxinebinding globulin (TBG), albumin, and TTR. Selectivity of ligands can be analyzed by displacement of labeled T4 from plasma. Samples of whole plasma are incubated with [ 125 I]T4 in the absence or presence of the tested compound, followed by separation of the serum T4 binding proteins by polyacrylamide gel electrophoresis [111] . In the absence of any added compound, three radioactive bands are observed in the gel, TBG followed by albumin and TTR. In the presence of a selective compound binding to TTR, weaker TTR bands relative to the other two are observed, whereas nonselective compounds will decrease the intensity of all three bands in the gel. The assay is qualitative but provides good indication about selectivity. It has been applied as a second screening test for many good ligands found by other methods, mainly turbidimetric assays. For instance, iododiflunisal, a iodinated diflunisal derivative, found to be a potent TTR fibrillogenesis inhibitor [102, 56] , showed high binding selectivity for TTR over the other plasma proteins, as opposed to diflunisal with lower selectivity. On the contrary, flufenamic acid binds selectively to TTR, but iodoflufenamic acid particularly inhibited binding of T4 to TGB [102] .
c.2. Plasma Binding Selectivity by Immunoprecipitation
Selectivity is evaluated by determining the stoichiometry of ligand binding to TTR in blood plasma, where other proteins can also bind the tested ligand. The candidate ligand is incubated with human plasma for 24 h. Then, TTR (free and in complex with the ligand) is immunoprecipitated with an anti-TTR antibody conjugated to Shepharose resin. The immunocaptured TTR is washed with buffer containing saponin as a necessary additive to prevent the non-specific interaction of the ligand with the antibodySepharose. Finally, the complex is dissociated at high pH and the binding stoichiometry of the small molecule relative to TTR is determined by reverse-phase high performance liquid chromatography [112] . In this way, selected NSAIDs that inhibit amyloid formation in vitro where assayed for plasma selectivity. NSAID drugs as flurbiprofen, fenoprofen and indomethacin did not bind to TTR in plasma, whereas flufenamic acid, mefenamic acid, meclofenamic acid, diflunisal, and diclofenac showed low selectivity at a concentration of 10.8 µM (0.1-0.2 molar equivalents of a maximum of 2 molar equivalents bound to TTR) even though they have submicromolar K d with isolated TTR. At a higher concentration, diflunisal improved binding to plasma TTR up to 0.86 molar equivalents at 224 µM, its maximum therapeutic concentration [112] .
The two reported plasma selectivity assays would be costly to be implemented in HTS format. As mentioned above, the recently reported Fluorescence conjugate competition assay is not only applied for in vitro ligand binding screening but also on human blood plasma to assess TTR plasma selectivity in the same assay, and it can be implemented in HTS format.
D. In Vitro Assays for Tetrameric TTR Stabilization
According to the fibrillogenesis pathway (Fig. 3) , the stabilization hypothesis establishes that small molecule ligands to the native TTR stabilize the tetrameric form and hence inhibit fibrillogenesis. The effect of TTR ligands can be evaluated by monitoring the stabilization they confer under denaturing condition, providing a further step towards selecting candidates targeted at native TTR stabilization as fibrillogenesis inhibitors.
d.1. Native TTR Stabilization Under Partially Denaturating Conditions
The effect of compounds on TTR stability has been evaluated using different protocols. With isolated native TTR resistance to SDS-induced denaturation at different pH values was utilized to measure the tetramer stability in the presence and absence of fibrillogenesis inhibitors [113] . On SDS-PAGE (polyacrylamide gel electrophoresis), TTR is observed as dimeric and monomeric species, the ratio depending of pH and TTR variants (the dimers correspond to tetrameric TTR in solution that are observed as dimers in the presence of SDS without boiling). Ligand binding to native TTR shifts the ratio tetramer/monomer to tetrameric species reflecting tetramer stabilization. Kinetics of unfolding on stronger denaturing conditions (6M urea) has been also used to evaluate tetramer stabilization by ligands. Kinetic stabilization can be measured by the rate of tetramer dissociation, which is assessed by linking the slow tetramer dissociation step to rapid monomer unfolding, easily quantified using tryptophan fluorescence or far-UV circular dichroism [114, 56] ).
An improved protocol uses human plasma to evaluate the stabilization of TTR. Native PAGE followed by isoelectric focusing (IEF) under partially denaturating conditions (with urea) is able to separate wt and variant TTR isoform [115] . Similarly, IEF under semi-denaturating conditions has been used to evaluate native TTR stabilization by small molecule ligands. Plasma samples of carriers of different TTR variants (i.e. homo and heterozygotic carriers of V30M) are incubated with the tested compound. The preparation is then subjected to native PAGE and the gel bands containing TTR are excised and applied to an IEF gel in the presence of 4M urea [116, 117] . These semi-denaturing conditions allow the visualization of bands corresponding to the TTR monomer and tetramer, and also to an oxidized form of the monomer. Increased tetramer to monomer ratios are observed for good ligands proving their stabilizing effect on native TTR [102, 118, 119] .
d.2. TTR Stabilization to Thermal Unfolding
The effect of ligands on the thermal stability of TTR is visualized by differential scanning calorimetry (DSC). TTR is highly stable with a midpoint of the thermal unfolding transition (T m ) of 101ºC at pH 7.4 for the wt protein [120] . The thermal unfolding of TTR is a spontaneous reversible process involving a highly co-operative transition between folded tetramers and unfolded monomers. Amyloidogenic variants are less stable than the wt under thermal unfolding conditions, but the order of stability does not correlate with their known amyloidogenic potential [100] . Depending on the experimental conditions, however, it has been reported that the thermal unfolding of some TTR variants is an irreversible process [121] . Ligands of tetrameric TTR increase the T m by 2 to 6ºC. A recent example is provided by a palindromic ligand, two molecules of a known TTR ligand 2-(3,5-dichloro-4-hydroxyphenylamino) benzoic acid joint by an alkyl linker, which increased the T m by 6.2ºC (wt TTR) or 5.9ºC (L55P TTR) [122] . The stabilizing effect shown by the ligands (ΔTm) is of the same order as the difference in Tm values observed for amyloidogenic and non-amyloidogenic TTR mutants.
It is observed, in support to the stabilization hypothesis by small ligands (namely iodinated diflunisal derivatives), that a relationship exist between ligand binding as ΔG binding from the dissociation constants measured by ITC, and thermal stabilization of the protein by the ligand as ΔG(T 0 ) (stabilization at the unfolding temperature of the free protein) from DSC (Planas et al. unpublished results).
E. Cellular Assays
Many cellular systems have been developed as models in drug discovery. Dysregulated cell death is a common feature of many human diseases, including cancer, stroke and neurodegeneration, and modulation of this cellular response has proved to be an effective therapeutic strategy [123] .
Cellular assays represent in vitro systems under closer physiological conditions than the previous in vitro assays, and are the next step in the validation of potential TTR fibrillogenesis inhibitors. For the implementation of cellular assays, two different approaches have been reported. One of them monitors fibril formation in transfected cells expressing human TTR, and hence, the effect of added compounds in inhibiting fibrillogenesis; and the other one evaluates TTR-induced cytotoxicity and the preventive effect of added molecules.
e.1. Cellular Assay for TTR Deposition
To set up a cellular system for the production of TTR aggregates, cells (Rat Schwannomas, RN22) were stably cotransfected with a cDNA TTR plasmid (wt, V30M or L55P). TTRtransfected cells express TTR upon induction which is secreted to the extracellular medium. Total extracellular TTR is quantified by an ELISA assay. The supernatant is applied to a cellulose acetate membrane filter to separate soluble proteins from aggregates. Insoluble TTR (aggregates / fibrils) are retained and immunodetected by an anti-TTR antibody (dot blot assay). Results showed that, in 24 h, TTR L55P forms aggregates in the medium, whereas, up to 72 h, wt TTR and V30M do not [104] .
Using TTR L55P transfected cells, inhibitors are added during the cell growth before and during induction of TTR expression, and extracellular TTR aggregates are quantified by the dot blot assay. Reduction of aggregates formed extracellularly relates with the inhibition potency of the tested compound [124] . One of the advantages of this cellular system is that it measures aggregation under good physiological conditions because: (i) it uses a eukaryotic system for the production of TTR; (ii) the secreted protein is not isolated, avoiding modifications such as oxidations that might influence aggregation; and (iii) aggregation occurs in the cell medium, under physiological pH and in the presence of serum proteins. Selected compounds known to be good TTR fibrillogenesis inhibitors in vitro were tested on this cellular system. Iododiflunisal, two anthranilic-based compounds [2-(3,5-dichlorophenyl) amino]benzoic acid and [2-(3,5-difluorophenyl) amino]benzoic acid]), a benzoxazole-based derivative, and triiodophenol (TIP) were able to prevent L55P aggregate formation in the conditioned medium, whereas diethylstilbestrol, resveratrol, diflunisal, genistein, diclofenac, diclonisal and flufenamic acid did not. These results reflect that good inhibitors in assays with isolated TTR and aggressive environment such as acid-induced fibrillogenesis do not necessarily behave as fibrillogenesis inhibitors in more physiological conditions.
e.2. Cellular Assay for TTR-Induced Cytotoxicity
In the last decade, several reports have stressed the importance of oligomeric intermediates as major cytotoxic species in various forms of amyloidosis, including Aβ peptide [125] , islet amyloid polypeptide [126] , or TTR [23, 24] although the debate about the precise nature of the cytotoxic species remains open. The amyloidogenic variant V30M TTR was cytotoxic to the human neuroblastoma cell line IMR-32, but not the wt TTR [127] . It was shown that amyloid fibrils and large soluble aggregates (>100 kDa) were not toxic, whereas monomeric TTR or relatively small, rapidly formed aggregates up to six subunits were the major cytotoxic species. wt TTR was not toxic to this cell line, probably due to the different stabilities of the native tetramers of both proteins, the wt being substantially more stable and less likely to populate the misfolded monomer or small aggregates pool.
This cellular assay has been adapted to test compounds for their activity as potential inhibitors of V30M TTR-induced cytotoxicity [128] . A pre-incubated solution of V30M TTR with the compound to be tested is added to the IMR-32 cell culture. Cell viability assays are then performed after different incubation periods to evaluate inhibition of cytotoxicity relative to control cultures. Selected NSAIDs and resveratrol were tested by this assay. Resveratrol and diflunisal were the most active inhibitors; flurbiprofen, flufenamic acid, indomethacin, and diclofenac were less active; and meclofenamic acid had no inhibitory activity. Good inhibitors in the cell assay are also good inhibitors in vitro (inhibition of acid-induced TTR fibrillogenesis), but exceptions were observed, namely meclofenamic and flufenamic acids, both good inhibitors of fibril formation in vitro but with no or modest effect in the cell assay, respectively. It again emphasizes that good inhibitors in assays with isolated TTR and aggressive environment do not necessarily behave as fibrillogenesis inhibitors in more physiological conditions. Recently, the same assay has been implemented with human cardiac AC16A cells [129] . Amyloidogenic TTR variants associated with FAC (V122I, V30M, V20I, and L111M) were toxic to the cardiomyocytes in a concentration-dependent manner, whereas the non-amyloidogenic variant T119M was not. In this cell line, TTR proteotoxicity correlates with the amyloidogenic potential of the TTR variant. Resveratrol analogs have been screened by the cardiac cell assay, concluding that resveratrol and its analogs stabilize the native tetramer preventing the formation of cytotoxic species. In addition, when using a cytotoxic monomeric variant of TTR (M-TTR), resveratrol induces the formation of large soluble non-toxic aggregates and some resveratrol analogs promoted tetramerization of monomeric TTR subunits, thus inhibiting cytotoxicity [129] .
The highly amyloidogenic Y78F TTR variant has also been used in a cell toxicity assay. Several natural polyphenols have potent inhibitory effects on amyloid fibril formation. Curcumin was shown to strongly suppress TTR amyloid formation by generating small "off-pathway" oligomers. The cytotoxicity of these polyphenol-induced oligomeric species was assayed with rat Schwannomas (RN22) cells incubated with Y78F TTR oligomers alone or pre-treated with polyphenols for 24h. Curcumin-induced oligomers significantly alleviated extracellular induced toxicity [119] .
F. Animal Models to Evaluate Amyloidosis Inhibitors

f.1. Mouse Models
Animal models for a variety of neurodegenerative disorders have been widely used to investigate mechanisms leading to disease and to assess possible therapeutic strategies (i.e. Huntington disease [130] , Parkinson's disease [131] , Alzheimer's diseases [132] , Prion disease [133] ). Several models have been created for FAP, including mice carrying the most prevalent TTR mutation, V30M, under the control of different promoters [134] [135] [136] , and a highly amyloidogenic TTR variant, L55P [137] . Unfortunately, up to date there is no mouse model for the cardiac mutant V122I. The characterization of these models revealed early presence of nonfibrillar deposits that with aging evolved to TTR amyloid deposits, thus mimicking the human pathological characteristics, except for the lack of deposits in the peripheral nerve. Doxycycline, shown to be a TTR fibril disrupter in vitro, when tested in transgenic TTR V30M mice was capable of disrupting Congo Red-positive amyloid deposits and decreases standard markers associated with fibrillar deposition (such as matrix metalloproteinase-9 and serum amyloid P component), being a potential drug in the treatment of amyloidosis [138] . However, doxycycline was unable to remove non-fibrillar TTR or to lower non-fibrillar TTR-associated markers. But remarkably, in combination with taurourcodeoxycholic acid, a synergic effect was observed with significant lowering of TTR deposition and associated tissue markers [139] . This drug combination has recently initiated clinical trials for TTR amyloidosis [40] .
Very recently, another improved FAP mouse model was generated, the V30M transgenic mice in a heat shock factor 1 (HSF-1) null background. These transgenic animals showed TTR deposition in extra-neural and neural tissues, and recapitulated pathological findings in FAP [140] .
f.2. Drosophila Models
Research has also been conducted to develop complementary systems for studies of TTR-associated amyloid diseases. Some authors have proposed Drosophila as a disease-model to study TTR amyloid formation, and to screen for pharmacological agents and modifying genes. Transgenic flies have been reported, expressing the clinical amyloidogenic mutant V30M [141] , the clinical amyloidogenic variant TTR L55P [142, 143] , and the engineered variant TTR-A (TTRV14N/V16E) (as well as the wild-type protein), all in secreted form. Within a few weeks, both mutants but not the wild-type TTR demonstrated a time-dependent aggregation of misfolded molecules. This was associated with neurodegeneration, change in wing posture, attenuation of locomotor activity including compromised flying ability and shortened life span. In contrast, expression of wild-type TTR had no discernible effect on either longevity or behavior.
Recent studies have demonstrated that heparan sulphate/heparin promoted TTR fibrillization through selective interaction with a basic motif of TTR. The effect of heparin on TTR fibril formation has been further demonstrated in the Drosophila model. Heparin was colocalized with TTR deposits in the head of the flies reared on heparin-supplemented medium, whereas no heparin was detected in the non-treated flies [144] . 
f.3. Monkey Model
Although TTR amyloidosis has not been reported in primates other than humans, very recently aged vervet monkeys that had the TTR Ile122 allele spontaneously developed TTR amyloidosis [145] . Recombinant expression of this TTR variant showed lower tetrameric stability and formed more amyloid fibrils than did the related TTR V122 from cynomolgus monkey. The authors propose that the Ile122 allele has an important role in TTR amyloidosis in the aged vervet monkey and that this monkey can serve as a valid pathological model of the human disease.
CONCLUSIONS
Current efforts for the treatment of TTR amyloidosis are addressed to prevent the formation of fibrils and prefibrillar toxic intermediates. TTR tetramer stabilization by small molecule ligand, immune therapy, and gene therapy are promising strategies based on our understanding of the pathogenesis of TTR amyloidosis. Many small molecule compounds targeting the formation, clearance, or assembly of toxic aggregates have been evaluated in the search of drug candidates as TTR fibrillogenesis inhibitors.
In this review we have compiled and classified most of the methods currently reported to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. A combination of different assays has to be used since they measure different properties along the fibrillogenesis pathway. They are classified ( Table 2 ) in primary and secondary screening, in vitro validation, and in vivo pre-clinical validation assays. Primary screening methods are those associated with acidic conditions and absence of serum proteins (in vitro fibrillogenesis inhibition), or those that measure binding to tetrameric TTR based on the tetramer stabilization hypothesis (in vitro ligand binding). They can be implemented in HTS format for initial selection of candidates. Secondary screening involves methods that evaluate selectivity for TTR over other plasma proteins and they are used to assay the positive candidates from the primary screening assays. To progress in selecting drug candidates, cellular assays are the common in vitro validation assays to evaluate the efficacy of the selected compounds (inhibition of TTRinduced cytotoxicity and inhibition of amyloid formation in cells). Finally, testing in animal models expressing amyloidogenic TTR variants provides the in vivo pre-clinical validation.
Primary and secondary screenings have been used to analyze many compounds and explore structure-activity relationships for ligand binding to native TTR and inhibition of TTR aggregation. However, the binding promiscuity shown by TTR, which accepts ligands with a high structural diversity, has precluded obtaining reliable models to predict efficacy. New assays are being developed for more efficient selection of drug candidates such as new high throughput screening methods, cellular assays, and animal models, as well as combined strategies with virtual screening approaches [146] [147] [148] [149] . Remarkable progress is being achieved in this area, including drug repurposing approaches [150] [151] [152] for orphan diseases to find new therapeutic applications to already existing drugs. The screening effort in the last years has brought several molecules to clinical trials:, the NSAID drug diflunisal, the orphan drug Tafamidis, approved in Europe in 2011 for FAP treatment, and recently, doxycycline in combination with tauroursodeoxycholic acid.
Innovative strategies being developed for other amyloidosis may inspire new approaches for TTR amyloidosis [153] . For example, the nonfibrillar plasma glycoprotein SAP (Serum Amyloid P component) is a universal constituent of amyloid deposits. Inhibition of binding of SAP to amyloid fibrils in vivo is a current strategy under development for systemic amyloidosis [154] [155] [156] [157] . A small molecule inhibitor, called CPHPC, was discovered from a screening program [154, 155] . Remarkably, a combination of it with an antibody resulted in a rapid breakdown of deposited amyloid in humans [156, 157] .
Integration of efficient screening methods with new approaches from other amyloidoses, are key milestones towards the development of therapeutic interventions of a broad spectrum of amyloid diseases.
